Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy

Thrombophilia in Assisted Reproductive Technology — Place and Needs of Thromboprophylaxis

“…In contrast to heparin, fondaparinux does not inhibit thrombin. Limited case-reports studies have shown effective treatment of inherited thrombophilia (Protein S deficiency) using Fondaparinux in case of heparin intolerance [149]. In situations where pregnant women cannot receive LMWH, fondaparinux may be a valuable alternative during pregnancy.…”

Venous thromboembolism in obese pregnant women: approach to diagnosis and management

“…No instances of HIT have been documented thus far with use of LMWH in pregnancy; nevertheless, it is worth mentioning that in cases of HIT or allergies to UFH/LMWH, heparanoids (i.e. fondaparinux or danaparoid), agents that lack cross-reactivity with HIT antibodies, may be considered during pregnancy following hematologic consultation [42,45,46].…”

Fondaparinux as an alternative anticoagulant therapy during pregnancy

“…Although it has been shown that transplacental passage can occur resulting in low measurable FXa activity in cord blood [11], no adverse outcomes in pregnancy have been reported in these four women. The other six separately published cases reported no adverse events to the mother or child [6][7][8][9][10]. In our hospital, experience with fondaparinux as an alternative in pregnant women has accumulated.…”

“…This has led to an increased frequency of incidentally detected thromboembolic events. Recent analyzes have explored the implications of such incidental events and it has been questioned whether these are truly asymptomatic events [8]. Additionally, in a recent retrospective analysis, 6-month mortality was similar in cancer patients with symptomatic or asymptomatic VTE but significantly higher in comparison to cancer patients without VTE [9].…”

“…Fondaparinux has been extensively studied for use in surgery prophylaxis and treatment of thromboembolic diseases [5]. However, data on the use of fondaparinux in pregnancy is limited to animal models and a few case reports [6][7][8][9][10]. Although it has been shown that transplacental passage can occur resulting in low measurable FXa activity in cord blood [11], no adverse outcomes in pregnancy have been reported in these four women.…”